Brokerage firm H.C. Wainwright Downgrades its rating on United Therapeutics Corporation(NASDAQ:UTHR). In a research note issued to the investors, the brokerage major Lowers the price-target to $95.00 per share. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by H.C. Wainwright was issued on Jun 15, 2016.
In a different note, On May 24, 2016, Argus Research said it Downgrades its rating on United Therapeutics Corporation. The shares have been rated ‘Hold’ by the firm. On Apr 29, 2016, Ladenburg Thalmann said it Downgrades its rating on United Therapeutics Corporation. The shares have been rated ‘Neutral’ by the firm.
United Therapeutics Corporation (UTHR) shares turned negative on Tuesdays trading session with the shares closing down -1.82 points or -1.76% at a volume of 6,00,882. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $104.27. The peak price level was also seen at $104.27 while the days lowest was $101.03. Finally the shares closed at $101.8. The 52-week high of the shares is $190.13 while the 52-week low is $101.03. According to the latest information available, the market cap of the company is $4,543 M.
United Therapeutics Corporation(UTHR) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $369.00M. Analysts had an estimated revenue of $395.02M. Earnings per share were $3.02. Analysts had estimated an EPS of $2.86.
Several Insider Transactions has been reported to the SEC. On Jun 13, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 1,277 shares at $115.86 per share price.Also, On Jun 10, 2016, Raymond Dwek (director) sold 3,000 shares at $166.28 per share price.On Jun 9, 2016, Tommy G Thompson (director) sold 2,000 shares at $115.62 per share price, according to the Form-4 filing with the securities and exchange commission.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.